Medicines Manufacturing Innovation Centre secures £42 million of funding for new manufacturing centre
4 September 2019
The Medicines Manufacturing Innovation Centre (MMIC) has secured £42 million of funding for a new manufacturing centre in Renfrewshire, Scotland. Currie & Brown has been appointed by CPI in partnership with the University of Strathclyde to provide project management, cost management and clerk of works services on the project. Funding has been provided by several sources including UK Research and Innovation, Scottish Enterprise, GlaxoSmithKline and AstraZeneca. Additional funds will come from revenue to be attracted from funding bids and commercial projects.
Scheduled to open in 2021, the new centre will become an international beacon for innovation in small molecule medicines manufacturing. It will incorporate capabilities for development and manufacturing of drug substances and drug products in a GMP-capable environment. This will allow the materials quantities used in process development to be minimised, and timelines to be accelerated to achieve just-in-time, right-first-time and real-time-release manufacturing principles.
Jack Keillor, associate director at Currie & Brown, said: “Using an array of advanced industry 4.0 manufacturing technologies, users will have the ability to evaluate, test and prototype processes. We are proud to be working closely with CPI to deliver a centre that will enhance the UK’s ability to manufacture advanced drug products.”